Grew full-year revenue to between $515 million and $517 million, an increase of 16%
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at...
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. ...
Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast...
Landmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025
USA News Group News Commentary
/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...